All News

A cancer survivor described the agony of making a life-or-death decision.

The Food and Drug Administration will speed up their review of Enhertu for previously treated patients with certain HER2-positive solid tumors.

Real-world data demonstrated that knowing a patient’s stage and subtype of renal cell carcinoma, a type of kidney cancer, may provide cancer teams with the information needed to determine potential prognosis and recurrence risk.

When Bob was first diagnosed and treated for follicular lymphoma, he refused to let the fear of the cancer returning dominate his life. Nearly 25 years later—after having experienced a relapse—Bob is still in remission and chooses to live his life to the fullest and celebrate life’s joys every day.

Subcutaneous Opdivo led to similar outcomes to intravenous administration of the drug and may be easier to access down the road, an expert said.

Patients with clear cell renal cell carcinoma had improved overall survival when treated with adjuvant Keytruda compared to placebo.

Findings from the ASCERTAIN trial support the use of oral Inqovi for adults with intermediate- and high-risk myelodysplastic syndromes (MDS) such as chronic myelomonocytic leukemia (CMML).

Fear overtook my mind as I received rounds of scans for prostate cancer when my PSA results surged.

Opdivo failed to improve disease-free survival in patients with localized renal cell carcinoma at high risk of relapse, according to findings from CheckMate 914.

Urinary minimal residual disease-negative status was related to preventing the return of cancer when certain patients with bladder cancer received Adstiladrin.

CURE® editors discuss last week’s biggest cancer headlines, from Dexter Scott King’s death to the potential of laughter therapy to boost quality of life.

Postsurgical Keytruda improved disease-free survival — but not overall survival — in patients with locally advanced, muscle-invasive bladder cancer.

Patients with previously untreated locally advanced or metastatic urothelial carcinoma experienced favorable progression-free survival, overall survival and objective response rates when treated with Padcev and Keytruda versus chemotherapy.

Patients with metastatic castration-resistant prostate cancer previously treated with external beam radiation therapy did not increase incidence of blood-related side effects with radium-223 compared with the overall population.

I never told my daughters what stage my lung cancer was. Was I being genuine?

Frontline treatment with Keytruda and Cabometyx produced responses with a manageable safety profile in patients with cisplatin-ineligible urothelial carcinoma, a type of bladder cancer.

Nubeqa plus androgen deprivation therapy and docetaxel to treat patients with metastatic hormone-sensitive prostate cancer lowered hospitalization rates but led to marginally longer lengths of stay compared with those treated with placebo, androgen deprivation therapy and docetaxel.

Patients with bladder cancer being treated with the immunotherapy agent, Keytruda, should not hesitate to call their oncology team if something does not feel right, an expert said.

Approximately 40% of patients with metastatic castration-resistant prostate cancer did not undergo certain types of tests that can be instrumental in treatment decisions.

Treatment with Zytiga, prednisone and Erleada plus another treatment regimen improved prostate cancer outcomes and did not change health-related quality of life outcomes.

My wife's simple sentence to me ended up saving my life from colorectal cancer.

From the Duchess of York receiving a skin cancer diagnosis to Selena Gomez contacting a fan with stage 4 disease, here’s what is happening in the oncology space this week.

Lynparza, Zytiga and prednisone led to improved progression-free survival and response rates in patients with metastatic prostate cancer.

Researchers claim to have determined the maximum=tolerated dose and usage of hypofractionated concurrent chemoradiation with an adaptive stereotactic ablative radiotherapy boost for patients with locally advanced unresectable non-small cell lung cancer, according to recently published findings.

Cabometyx plus Tecentriq led to improved progression-free survival compared with novel hormonal therapy in patients with metastatic castration-resistant prostate cancer.

A CAR NK therapy made from cord blood showed promising responses in patients with relapsed or refractory B-cell malignancies.

I've found that making time for a good laugh each day helped break through the looming thought of cancer.

Dr. Dustin Deming, a gastrointestinal oncologist, began his own cancer journey more than a decade ago when he received a diagnosis of rectal cancer.

Circulating tumor DNA can be a valuable tool in gastric cancer, but unanswered questions remain, an expert said.